Cited by 29Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional DevelopmentPharmaceutical studies and practices

Effects of Clonidine and Methylphenidate on Family Quality of Life in Attention-Deficit/Hyperactivity Disorder

Open access
Cannon, Michael, Pelham, William H., Sallee, F. Randy, Palumbo, Donna R., Bukstein, Oscar, Daviss, W. Burl·2009·Journal of Child and Adolescent Psychopharmacology

Abstract

Objective: The aim of this study was to determine the effect on family quality of life (QOL) of clonidine (CLON) and methylphenidate (MPH), used alone and in combination, in treating attention-deficit/hyperactivity disorder (ADHD). Methods: Two proxy QOL measures were used in a multicenter, double-blind, placebo-controlled 16-week trial of 122 children, ages 7–12 years, with ADHD. Children were randomized to one of four groups in which they received MPH, CLON, a combination of drugs, or placebo. QOL was measured with the Daily Hassles Scale and the Impact on Family Scale at baseline and at 16 weeks. Results: In a general linear model repeated measures analysis, treatment groups improved over a 16-week period compared to placebo for Daily Hassles and Impact on Family, as well as in symptoms measured by the ADHD Rating Scale. QOL measures correlated moderately with efficacy and symptom measures. Conclusion: This study provides evidence that measures of QOL for the family are sensitive to pharmacological treatment of ADHD. The correlation pattern of the QOL measures with symptom and efficacy variables supported family QOL as a related but separate construct. Clonidine for Attention-Deficit/Hyperactivity Disorder Treatment Study (CAT) Trial Registry Name: Clinicaltrials.gov; ID Number, NCT00031395; URL, http://clinicaltrials.gov/ct/show/NCT00031395?order=8/ .

Integrity signals

Registry

Crossref · 10.1089/cap.2009.0008

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The broad improvements in participant-perceived QOL observed in this trial are in line with those previously described with psychostimulant and nonstimulant treatment in children, adolescents, and adults with ADHD.

    “The broad improvements in participant-perceived QOL observed currently are in line with those described previously with psychostimulant and nonstimulant treatment in children, adolescents, and adults with ADHD (Spencer et al. 2008; Cannon et al. 2009; Gerwe et al. 2009; Brown and Landgraf 2010; Wehmeier et al. 2010; Berek et al. 2011; Brams et al. 2011).”
  • Adding clonidine to methylphenidate, extended-release guanfacine to stimulants, or OROS methylphenidate to atomoxetine improved residual ADHD symptoms and was well tolerated.

    “Recent studies have shown that adding clonidine to methylphenidate [95], extended-release guanfacine to stimulants [96], or OROS methylphenidate to atomoxetine [97] improved residual ADHD symptoms and was well tolerated.”

    From Advances in understanding and treating ADHD (2011) · cites this paper as [95]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cannon, M., Pelham, W. H., Sallee, F. R., Palumbo, D. R., Bukstein, O., & Daviss, W. B.
Affiliations
  • University of Cincinnati (US)
  • SUNY Buffalo
  • Pfizer (United States) (US)
  • University of Pittsburgh (US)
  • University of Texas Health Science Center at San Antonio
Corresponding author
Cannon, Michael
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2009-10
Volume
19
Issue
5
Pages
511-517
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W1964396391
Cited by
29
References
30
Citations by year
2026: 2 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2019: 3 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 1
FWCI
1.85
Type
journal article
Language
en
Open access
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS039087)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
attention deficit hyperactivity disorder, clonidine, methylphenidate, family quality of life, combination pharmacotherapy, children, family impact, daily hassles, ADHD medication
MeSH terms
Adrenergic alpha-Agonists, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Clonidine, Double-Blind Method, Drug Therapy, Combination, Family Health, Female, Humans, Male, Methylphenidate, Psychiatric Status Rating Scales, Quality of Life, Linear Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review